An error has occurred while submitting. Please try again later...
Your form was submitted successfully
In an increasingly complex healthcare environment, surgeons are faced with unique challenges that can negatively affect outcomes. Effectively managing the risk of postoperative complication is a priority.
Proactive Risk Management (PRM) with 3M™ Prevena™ Therapy provides healthcare professionals with an evidence-based, standardized approach that helps to advance the standard of care for closed incision negative pressure therapy (ciNPT). This intuitive, actionable model is grounded in level 1, 2 and 3 clinical evidence to help support you through procedural and patient risk stratification.
EXPRESS_Fishawack Health | 18667_3M_Prevena_PRM_Video_VF Every day, you make the best decisions for your patients based on your training, your experience, your clinical judgment, grounded in clinical evidence. Proactive Risk Management with 3M Prevena Therapy or PRM is an evidence based standardized approach that helps advance the standard of care for closed incision negative pressure therapy. With the costly reality of at risk surgical patient, proactively reducing the risk of post-operative complications is a priority. Prevena therapy has demonstrated significant improvement in key patient outcomes across multiple specialties. PRM gives you resources and tools to help support your decision making and optimize outcomes. And it's all grounded in level 1, 2, and 3 clinical evidence. Help advance the standard of care with Proactive Risk Management with Prevena Therapy, and get more control over postoperative healing.
This scientifically engineered, advanced dressing therapy is the first closed-incision negative pressure therapy (ciNPT) solution of its kind to help reduce the risk or incidence of seromas and superficial surgical site infections in Class I and II wounds.**
*In a canister
**The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seromas in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at HCBGRegulatory.3m.com.
In a newly published 2023 Multi-Specialty Meta-Analysis, Prevena Therapy has demonstrated significant improvement in key patient outcomes across multiple specialties.⁹
Prevena Central is your one-stop platform for all things Prevena Therapy. Designed with busy healthcare professionals in mind, Prevena Central provides incision management resources that help advance the standard of care.
Contact a 3M representative for information or to request a demonstration.
NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.
3M™Prevena™ Therapy Indications for Use:
3M™Prevena™ 125 Therapy Unit and 3M™ Prevena™ Plus 125 Therapy Unit manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125 mmHg continuous negative pressure.
When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma; and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds. The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at hcbgregulatory.3m.com.
3M™ Prevena™ Restor™ Therapy Indications for Use: The 3M™ Prevena Restor™ Incision Management System is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy.
References
1.Zimlichman E, Henderson D, Tamir, et al. Health care-associated Infections a meta-analysis of costs and financial impact on the U.S. health care system. JAMA Interned.2013;173(22):20-46.
2. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated Infections. N Engl JMed: 2014;370:1198-208.
3. Shepard J, Ward W, Milstone A, et al. Financial impact of surgical site infections on hospitals. The hospital management perspective. JAMA Surg. 2013;148(10):907-914.doi:10.1001/jamasurg.2013.2246 Published online August 21, 2013.
4. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290(14):1868-1874.
5. Wilkes RP, Kilpadi DV, Zhao Y, et al. Closed Incision Management With Negative Pressure Wound Therapy (CIM): Biomechanics.Surgical Innovation. 2012;19(1):67-75.
6. Kilpadi DV, Cunningham MR. Evaluation of closed incision management with negative pressure wound therapy (CIM): hematoma/seroma and involvement of the lymphatic system. Wound Repair Regen. 2011;19(5):588-596.
7. Glaser DA, Farnsworth CL, Varley ES, et al. Negative pressure therapy for closed spine incisions: a pilot study. Wounds. 2012;24(11):308-316.
8. Wilkes RP, Kilpadi DV, Zhao Y, et al. Closed Incision Management With Negative Pressure Wound Therapy (CIM): Biomechanics. Surgical Innovation. 2012;19(1):67-75.
9. Cooper HJ, Singh DP, Gabriel A, Mantyh C, Silverman R, Griffin L. Closed Incision Negative Pressure Therapy Versus Standard of Care Over Closed Surgical Incisions in the Reduction of Surgical Site Complications: A Systematic Review and Meta-Analysis of Comparative Studies. Plastic and Reconstructive Surgery – Global Open. 2023 Mar 16;11(3):e4722.